Abbonarsi

Implementation of guideline recommendations and outcomes in patients with idiopathic pulmonary fibrosis: Data from the IPF-PRO registry - 08/12/21

Doi : 10.1016/j.rmed.2021.106637 
Joao A. de Andrade a, , Tejaswini Kulkarni b, Megan L. Neely c, d, Anne S. Hellkamp c, d, Amy Hajari Case e, Kalpalatha Guntupalli f, Shaun Bender g, Craig S. Conoscenti g, Laurie D. Snyder c, d
on behalf of the

on behalf of the IPF-PRO Registry investigators

a Vanderbilt University School of Medicine, Nashville, TN, USA 
b University of Alabama at Birmingham, Birmingham, AL, USA 
c Duke Clinical Research Institute, Durham, NC, USA 
d Duke University Medical Center, Durham, NC, USA 
e Piedmont Healthcare, Atlanta, GA, USA 
f Baylor College of Medicine, Houston, TX, USA 
g Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, CT, USA 

Corresponding author. Vanderbilt University School of Medicine, Nashville, TN, 37232, USA.Vanderbilt University School of MedicineNashvilleTN37232USA

Abstract

Background

Few data are available on the extent to which clinical practice is aligned with international guidelines for the management of idiopathic pulmonary fibrosis (IPF). We investigated the extent to which management guidelines for IPF have been implemented in the US IPF-PRO Registry and associations between implementation of guidelines and clinical outcomes.

Methods

We assessed the implementation of eight recommendations in clinical practice guidelines within the 6 months after enrollment: visit to a specialized clinic; pulmonary function testing; use of oxygen in patients with resting hypoxemia and exercise-induced hypoxemia; referral for pulmonary rehabilitation; treatment of gastro-esophageal reflux disease; initiation of anti-fibrotic therapy; referral for lung transplant evaluation. An implementation score was calculated as the number of recommendations achieved divided by the number for which the patient was eligible. Associations between implementation score and outcomes were analyzed using logistic regression and Cox proportional hazards models.

Results

Among 727 patients, median (Q1, Q3) implementation score was 0.6 (0.5, 0.8). Patients with an implementation score >0.6 had greater disease severity than those with a lower score. Implementation was lowest for referral for pulmonary rehabilitation (19.5%) and lung transplant evaluation (22.3%). In unadjusted models, patients with higher implementation scores had a greater risk of death, death or lung transplant, and hospitalization, but no significant associations were observed in adjusted models.

Conclusions

Management guidelines were more likely to be implemented in patients with IPF with greater disease severity. When adjusted for disease severity, no association was found between implementation of management guidelines and clinical outcomes.

Il testo completo di questo articolo è disponibile in PDF.

Graphical abstract




Image 1

Il testo completo di questo articolo è disponibile in PDF.

Highlights

We investigated the implementation of guidelines for the management of IPF.
Guidelines were more likely to be implemented in patients with more severe disease.
In adjusted models, there were no associations between guideline use and outcomes.

Il testo completo di questo articolo è disponibile in PDF.

Keywords : Lung disease, Interstitial pulmonary fibrosis, Guideline, Hospitalization, Mortality

Abbreviations : ALAT, ATS, BMI, CASA-Q, DLco, EQ-5D, ERS, FEV1, FVC, GERD, IPF, JRS, MCS, PCS, SGRQ, SF-12, VAS


Mappa


© 2021  The Authors. Pubblicato da Elsevier Masson SAS. Tutti i diritti riservati.
Aggiungere alla mia biblioteca Togliere dalla mia biblioteca Stampare
Esportazione

    Citazioni Export

  • File

  • Contenuto

Vol 189

Articolo 106637- novembre 2021 Ritorno al numero
Articolo precedente Articolo precedente
  • A new standard scoring for interstitial pneumonia based on quantitative analysis of ultrasonographic data: A study on COVID-19 patients
  • Fiorella Anna Lombardi, Roberto Franchini, Rocco Morello, Ernesto Casciaro, Stefania Ianniello, Maurizio Serra, Francesco Satriano, Francesco Mojoli, Silvia Mongodi, Daniela Pignatelli, Marco Di Paola, Sergio Casciaro
| Articolo seguente Articolo seguente
  • Comparing initial LABA-ICS inhalers in COPD: Real-world effectiveness and safety
  • Samy Suissa, Sophie Dell’Aniello, Pierre Ernst

Benvenuto su EM|consulte, il riferimento dei professionisti della salute.
L'accesso al testo integrale di questo articolo richiede un abbonamento.

Già abbonato a @@106933@@ rivista ?

@@150455@@ Voir plus

Il mio account


Dichiarazione CNIL

EM-CONSULTE.COM è registrato presso la CNIL, dichiarazione n. 1286925.

Ai sensi della legge n. 78-17 del 6 gennaio 1978 sull'informatica, sui file e sulle libertà, Lei puo' esercitare i diritti di opposizione (art.26 della legge), di accesso (art.34 a 38 Legge), e di rettifica (art.36 della legge) per i dati che La riguardano. Lei puo' cosi chiedere che siano rettificati, compeltati, chiariti, aggiornati o cancellati i suoi dati personali inesati, incompleti, equivoci, obsoleti o la cui raccolta o di uso o di conservazione sono vietati.
Le informazioni relative ai visitatori del nostro sito, compresa la loro identità, sono confidenziali.
Il responsabile del sito si impegna sull'onore a rispettare le condizioni legali di confidenzialità applicabili in Francia e a non divulgare tali informazioni a terzi.


Tutto il contenuto di questo sito: Copyright © 2026 Elsevier, i suoi licenziatari e contributori. Tutti i diritti sono riservati. Inclusi diritti per estrazione di testo e di dati, addestramento dell’intelligenza artificiale, e tecnologie simili. Per tutto il contenuto ‘open access’ sono applicati i termini della licenza Creative Commons.